RxDoctor Payments Data

Monica Divakaruni, MD

Cardiovascular Disease · Saint Helena, CANPI 1205883972

Payments from drug & device makers

$68,393in general payments, 2019–2025

Across 872 payments — averaging $78.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$36K
  • Abbott$10K
  • Boston Scientific$8K
  • Edwards Lifesciences$3K
  • Biotronik Inc.$2K
  • Cardiovascular Systems Inc.$2K
  • plus $8K from 32 others

What the payments were for

  • Consulting fees$3601%
  • Speaking & faculty fees$14,46421%
  • Travel & lodging$15,48823%
  • Food & beverage$38,07056%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$68,393 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$423,535
Medicare patients
1,046
Services billed
3,401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban400$395,051
EntrestoSacubitril/Valsartan201$237,759
Repatha SureclickEvolocumab247$227,142
XareltoRivaroxaban90$112,378
JardianceEmpagliflozin63$69,966
Praluent PenAlirocumab56$51,532
BrilintaTicagrelor18$10,619
Ezetimibe293$7,920
Ranolazine ErRanolazine95$6,793
Rosuvastatin Calcium455$6,244
Nebivolol Hcl48$5,524
Metoprolol Succinate483$5,343
Atorvastatin Calcium546$4,305
Losartan Potassium535$4,195
Fenofibrate48$2,993

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$225$395,051400 claims
NovartisEntresto$786$237,759201 claims
Johnson & JohnsonXarelto$201$112,37890 claims
Boehringer IngelheimJardiance$190$69,96663 claims
AstraZenecaBrilinta$206$10,61918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Saint Helena

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →